1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Is Arsenic Exposure a Risk Factor for Metabolic Syndrome? A Review of the Potential Mechanisms

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Exposure to arsenic in drinking water is a worldwide health problem. This pollutant is associated with increased risk of developing chronic diseases, including metabolic diseases. Metabolic syndrome (MS) is a complex pathology that results from the interaction between environmental and genetic factors. This condition increases the risk of developing type 2 diabetes, cardiovascular diseases, and cancer. The MS includes at least three of the following signs, central obesity, impaired fasting glucose, insulin resistance, dyslipidemias, and hypertension. Here, we summarize the existing evidence of the multiple mechanisms triggered by arsenic to developing the cardinal signs of MS, showing that this pollutant could contribute to the multifactorial origin of this pathology.

          Related collections

          Most cited references239

          • Record: found
          • Abstract: found
          • Article: not found

          2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018.

          (2017)
          The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mechanisms of Insulin Action and Insulin Resistance

            The 1921 discovery of insulin was a Big Bang from which a vast and expanding universe of research into insulin action and resistance has issued. In the intervening century, some discoveries have matured, coalescing into solid and fertile ground for clinical application; others remain incompletely investigated and scientifically controversial. Here, we attempt to synthesize this work to guide further mechanistic investigation and to inform the development of novel therapies for type 2 diabetes (T2D). The rational development of such therapies necessitates detailed knowledge of one of the key pathophysiological processes involved in T2D: insulin resistance. Understanding insulin resistance, in turn, requires knowledge of normal insulin action. In this review, both the physiology of insulin action and the pathophysiology of insulin resistance are described, focusing on three key insulin target tissues: skeletal muscle, liver, and white adipose tissue. We aim to develop an integrated physiological perspective, placing the intricate signaling effectors that carry out the cell-autonomous response to insulin in the context of the tissue-specific functions that generate the coordinated organismal response. First, in section II, the effectors and effects of direct, cell-autonomous insulin action in muscle, liver, and white adipose tissue are reviewed, beginning at the insulin receptor and working downstream. Section III considers the critical and underappreciated role of tissue crosstalk in whole body insulin action, especially the essential interaction between adipose lipolysis and hepatic gluconeogenesis. The pathophysiology of insulin resistance is then described in section IV. Special attention is given to which signaling pathways and functions become insulin resistant in the setting of chronic overnutrition, and an alternative explanation for the phenomenon of ‟selective hepatic insulin resistanceˮ is presented. Sections V, VI, and VII critically examine the evidence for and against several putative mediators of insulin resistance. Section V reviews work linking the bioactive lipids diacylglycerol, ceramide, and acylcarnitine to insulin resistance; section VI considers the impact of nutrient stresses in the endoplasmic reticulum and mitochondria on insulin resistance; and section VII discusses non-cell autonomous factors proposed to induce insulin resistance, including inflammatory mediators, branched-chain amino acids, adipokines, and hepatokines. Finally, in section VIII, we propose an integrated model of insulin resistance that links these mediators to final common pathways of metabolite-driven gluconeogenesis and ectopic lipid accumulation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              What we talk about when we talk about fat.

              There has been an upsurge of interest in the adipocyte coincident with the onset of the obesity epidemic and the realization that adipose tissue plays a major role in the regulation of metabolic function. The past few years, in particular, have seen significant changes in the way that we classify adipocytes and how we view adipose development and differentiation. We have new perspective on the roles played by adipocytes in a variety of homeostatic processes and on the mechanisms used by adipocytes to communicate with other tissues. Finally, there has been significant progress in understanding how these relationships are altered during metabolic disease and how they might be manipulated to restore metabolic health. Copyright © 2014 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                URI : https://loop.frontiersin.org/people/1684434
                URI : https://loop.frontiersin.org/people/1370117
                URI : https://loop.frontiersin.org/people/1230170
                URI : https://loop.frontiersin.org/people/1712452
                URI : https://loop.frontiersin.org/people/1311690
                URI : https://loop.frontiersin.org/people/1720716
                URI : https://loop.frontiersin.org/people/1583512
                URI : https://loop.frontiersin.org/people/1712395
                URI : https://loop.frontiersin.org/people/20631
                Journal
                Front Endocrinol (Lausanne)
                Front Endocrinol (Lausanne)
                Front. Endocrinol.
                Frontiers in Endocrinology
                Frontiers Media S.A.
                1664-2392
                16 May 2022
                2022
                : 13
                : 878280
                Affiliations
                [1] 1 Department of Cognitive Neurosciences, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México , Mexico City, Mexico
                [2] 2 Department of Genomic Medicine and Environmental Toxicology. Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México , Mexico City, Mexico
                Author notes

                Edited by: Francisco Westermeier, FH Joanneum, Austria

                Reviewed by: Romina Bertinat, University of Concepcion, Chile; Robert Sargis, University of Illinois at Chicago, United States

                *Correspondence: Marcia Hiriart, mhiriart@ 123456ifc.unam.mx

                This article was submitted to Diabetes: Molecular Mechanisms, a section of the journal Frontiers in Endocrinology

                Article
                10.3389/fendo.2022.878280
                9150370
                35651975
                87e60479-4dc3-4740-9afc-39ff466b3624
                Copyright © 2022 Pánico, Velasco, Salazar, Picones, Ortiz-Huidobro, Guerrero-Palomo, Salgado-Bernabé, Ostrosky-Wegman and Hiriart

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 17 February 2022
                : 11 April 2022
                Page count
                Figures: 4, Tables: 1, Equations: 0, References: 241, Pages: 24, Words: 13226
                Categories
                Endocrinology
                Review

                Endocrinology & Diabetes
                metabolic syndrome,arsenic,beta-cell,insulin resistance,obesity,cardiovascular diseases

                Comments

                Comment on this article